(Q38441757)

English

Early development of castrate resistance varies with different dosing regimens of luteinizing hormone releasing hormone agonist in primary hormonal therapy for prostate cancer

scientific article published on 15 December 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Early development of castrate resistance varies with different dosing regimens of luteinizing hormone releasing hormone agonist in primary hormonal therapy for prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

author name string

Jeremy M Blumberg

1

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Eric O Kwon

2

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

T Craig Cheetham

3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Fang Niu

4

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Charles E Shapiro

5

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Judith Pacificar

6

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Ronald K Loo

7

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Stephen G Williams

8

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Gary W Chien

9

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

language of work or name

0 references

publication date

15 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

77

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

412-416

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.08.037

7 January 2021

Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.08.037

7 January 2021

Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.08.037

7 January 2021

Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.08.037

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.08.037

7 January 2021

Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.08.037

7 January 2021

Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.08.037

7 January 2021

Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.08.037

7 January 2021

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.08.037

7 January 2021

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.08.037

7 January 2021

Identifiers

10.1016/J.UROLOGY.2010.08.037

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

release_hypp4r35t5eaddxwrj7u5hvoja

1 reference

https://api.fatcat.wiki/v0/release/hypp4r35t5eaddxwrj7u5hvoja

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38441757&oldid=1844294105"